依达拉奉对老年阻塞性睡眠呼吸暂停低通气综合征患者血清炎症因子和黏附分子的影响

目的探讨依达拉奉对老年阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和细胞间黏附分子-1(ICAM-1)的影响及临床意义。方法选择2016年2月至2017年10月华北理工大学附属医院呼吸科收治的90例经多导睡眠监测确诊的中重度老年OSAHS患者,根据随机数字表法随机分为A、B、C三组,每组30例。A组患者予以持续气道正压通气治疗6个月,B组患者在予以持续气道正压通气治疗的同时接受依达拉奉治疗6个月,C组仅单独予以依达拉奉治疗6个月。分别于治疗前及治疗6个月后采用酶联免疫吸附测定法检测血清TNF-α、IL-6及ICAM-1水平的变化,进行对比分析。结果三组患者治疗前血清TNF-α、IL-6及ICAM-1水平相比,差异无统计学意义(P>0.05)。与治疗前比较,三组患者治疗6个月后血清TNF-α、IL-6及ICAM-1水平均明显下降(P<0.05)。治疗6个月后,A、B两组血清TNF-α、IL-6及ICAM-1较C组水平明显下降(P<0.05),B组较A组明显下降(P<0.05)。结论依达拉奉可以抑制中重度老年OSAHS患者血清TNF-α、IL-6及ICAM-1的表达,进而可能减轻血管内皮功能紊乱及损伤。

Effects of edaravone on serum inflammatory factors and adhesion molecules in elderly OSAHS patients

Objective To investigate the effects and clinical significance of edaravone on serum tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) and intercellular adhesion molecule-1(ICAM-1) in elderly patients with obstructive sleep apnea hypopnea syndrome(OSAHS). Methods A total of 90 elderly patients with moderate to severe OSAHS confirmed by polysomnography were recruited from North China University of Science and Technology Affiliated Hospital in February 2016 to October 2017. According to random number table method the OSAHS patients were randomly divided into group A(n=30), group B(n=30) and group C(n=30). Group A received continuous positive airway pressure treatment for six months, group B received edaravone therapy and continuous positive airway pressure treatment for six months, and group C only received edaravone therapy for six months. The changes of serum TNF-α, IL-6 and ICAM-1 were detected by enzyme-linked immunosorbent assay before and after treatment. Results The differences of serum TNF-α, IL-6 and ICAM-1 before treatment in the three groups were not statistically significant(P>0.05).Compared with before treatment, the levels of serum TNF-α, IL-6 and ICAM-1 decreased in the three groups(P<0.05).After six months of treatment, the levels of serum TNF-α, IL-6 and ICAM-1 decreased in group A and group B compared with group C(P<0.05), and decreased significantly in group B compared with group A(P<0.05). Conclusion Edaravone can inhibit the expressions of serum TNF-α, IL-6 and ICAM-1 in elderly patients with moderate to severe OSAHS, and thereby reduce vascular endothelial dysfunction and injury.